Received Oct 6, 2025
| Type | Name | Manufacturer | Dose | Lot | Route / Site |
|---|---|---|---|---|---|
| TDAP | TDAP (BOOSTRIX) | GLAXOSMITHKLINE BIOLOGICALS | UNK | — | — |
Boostrix use in patients younger than 10 years of age; This non-serious case was reported by a nurse via call center representative and described the occurrence of inappropriate age at vaccine administration in unspecified number of patients who received DTPa (Reduced antigen) (Boostrix) for prophylaxis. On an unknown date, the patients received Boostrix. On an unknown date, an unknown time after receiving Boostrix, the patients experienced inappropriate age at vaccine administration (Verbatim: Boostrix use in patients younger than 10 years of age). The outcome of the inappropriate age at vaccine administration was not applicable. This report is made by GSK without prejudice and does not imply any admission or liability for the incident or its consequences. Additional Information: GSK receipt date: 22-Sep-2025 A nurse reported that she had been working in her clinic for several years and they often use Boostrix for catch-up vaccination in patients 7 to 8 year-old. Recently, one of the staff members realized that as per PI of Boostrix, it was approved for patients aged 10 years and older. They wanted clarification about the age indication for Boostrix. No further details provided.